Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. NEO
stocks logo

NEO

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
188.40M
+9.53%
0.024
-52.3%
187.98M
+11.87%
0.042
+4.17%
Estimates Revision
The market is revising Upward the revenue expectations for NeoGenomics, Inc. (NEO) for FY2025, with the revenue forecasts being adjusted by 0.43% over the past three months. During the same period, the stock price has changed by 48.87%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.43%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-0.91%
In Past 3 Month
Stock Price
Go Up
up Image
+48.87%
In Past 3 Month
Wall Street analysts forecast NEO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NEO is 13.67 USD with a low forecast of 11.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
Wall Street analysts forecast NEO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NEO is 13.67 USD with a low forecast of 11.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
6 Hold
0 Sell
Moderate Buy
Current: 11.850
sliders
Low
11.00
Averages
13.67
High
17.00
Current: 11.850
sliders
Low
11.00
Averages
13.67
High
17.00
Piper Sandler
Overweight
maintain
$11 -> $12
2025-11-10
Reason
Piper Sandler
Price Target
$11 -> $12
2025-11-10
maintain
Overweight
Reason
Piper Sandler raised the firm's price target on NeoGenomics to $12 from $11 following quarterly results. The firm keeps an Overweight rating on the shares.
BofA
Neutral
maintain
$11
2025-10-29
Reason
BofA
Price Target
$11
2025-10-29
maintain
Neutral
Reason
BofA raised the firm's price target on NeoGenomics to $11 from $6.50 and keeps a Neutral rating on the shares after "a solid quarter." The firm views the quarterly update as "constructive," but sees questions on the sustainability of the growth rate and the competitive position, the analyst tells investors.
Leerink
Market Perform
maintain
$12 -> $14
2025-10-28
Reason
Leerink
Price Target
$12 -> $14
2025-10-28
maintain
Market Perform
Reason
Leerink raised the firm's price target on NeoGenomics to $14 from $12 and keeps a Market Perform rating on the shares. The company reported a Q3 beat and is taking investor feedback by proving "beatable guidance and realistic targets," the analyst tells investors in a research note.
TD Cowen
Buy
upgrade
$10 -> $12
2025-09-12
Reason
TD Cowen
Price Target
$10 -> $12
2025-09-12
upgrade
Buy
Reason
TD Cowen raised the firm's price target on NeoGenomics to $12 from $10 and keeps a Buy rating on the shares after hosting meetings with management. The firm left more constructive on NeoGenomics's new product launches, saying MolDX reimbursement remains the "final gate" for a 2026 ramp.
Stephens
Overweight
maintain
$11
2025-09-02
Reason
Stephens
Price Target
$11
2025-09-02
maintain
Overweight
Reason
Stephens raised the firm's price target on NeoGenomics (NEO) to $11 from $6.50 and keeps an Overweight rating on the shares after the company announced that a North Carolina district court ruled in the company's favor in the litigation with Natera (NTRA). The ruling grants NeoGenomics the ability to broadly commercialize RaDaR ST and removes an overhang, says the analyst, who believes the decision strengthens NeoGenomics' positioning in oncology and helps to support more durable growth.
Piper Sandler
Overweight
downgrade
$12 -> $11
2025-08-04
Reason
Piper Sandler
Price Target
$12 -> $11
2025-08-04
downgrade
Overweight
Reason
Piper Sandler lowered the firm's price target on NeoGenomics to $11 from $12 following quarterly results. The firm keeps an Overweight rating on the shares.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Neogenomics Inc (NEO.O) is 78.59, compared to its 5-year average forward P/E of 0.26. For a more detailed relative valuation and DCF analysis to assess Neogenomics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
0.26
Current PE
78.59
Overvalued PE
126.75
Undervalued PE
-126.22

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
120.09
Current EV/EBITDA
33.72
Overvalued EV/EBITDA
1435.36
Undervalued EV/EBITDA
-1195.19

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
4.40
Current PS
1.95
Overvalued PS
7.82
Undervalued PS
0.98
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

NEO News & Events

Events Timeline

(ET)
2025-10-30
12:54:00
NeoGenomics to Showcase RaDaR ST Bridging Study at ISLB 2025
select
2025-10-28 (ET)
2025-10-28
07:39:33
NeoGenomics Supports FY25 Revenue Forecast of $720M-$726M, Aligning with Consensus of $722.46M
select
2025-10-28
07:36:59
NeoGenomics announces Q3 adjusted EPS of 3 cents, surpassing consensus estimate of 2 cents.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
04:41 AMPRnewswire
Netmarble Unveils New Trailer for The Seven Deadly Sins: Origin, Global Pre-Registration Now Open
  • Trailer Release: Netmarble unveiled a new trailer for The Seven Deadly Sins: Origin at The Game Awards 2025, showcasing high-resolution graphics powered by Unreal Engine 5 and immersive storytelling, which captivated global audiences and heightened market anticipation for the game.
  • Multiverse Narrative: The trailer emphasized the game's multiverse narrative, featuring characters like Meliodas and Tristan flying over Britannia, highlighting the expansive open-world experience that enhances players' desire for exploration and engagement.
  • Cooperative Combat Mechanic: The game's real-time cooperative raid battles allow players to team up to defeat powerful bosses, underscoring its core feature as a multiplayer-driven open-world RPG, which is expected to enhance player interaction and game stickiness.
  • Strong Testing Feedback: In an October global closed beta test, 95% of participants expressed willingness to continue playing after launch, indicating the game's appeal and market potential, suggesting a promising outlook for its official release.
[object Object]
Preview
3.5
12-10Businesswire
NeoGenomics to Present RaDaR®1.0 Data at 2025 San Antonio Breast Cancer Symposium
  • Data Presentation: NeoGenomics will showcase new data from its RaDaR®1.0 assay for molecular residual disease (MRD) detection at the 2025 San Antonio Breast Cancer Symposium, highlighting its significance in early breast cancer research.
  • Clinical Trial Results: The presentation will include findings from the SURVIVE HERoes Phase III trial and the CLEVER study, demonstrating the effectiveness of RaDaR 1.0 circulating tumor DNA testing in assessing recurrence risk, which may drive clinical adoption.
  • Industry Impact: CEO Tony Zook emphasized that ctDNA detected by RaDaR provides actionable insights for patient monitoring, potentially transforming routine care practices for community oncologists and improving patient outcomes.
  • Company Background: NeoGenomics is a leading cancer diagnostics company offering a comprehensive range of cancer genetics testing services, dedicated to providing innovative diagnostic and predictive testing to assist oncologists and patients in early cancer diagnosis and treatment.
[object Object]
Preview
3.5
12-10Newsfilter
NeoGenomics Presents RaDaR Assay Data at 2025 SABCS for Breast Cancer Monitoring
  • Research Presentation: NeoGenomics will showcase new data on its RaDaR®1.0 assay at the 2025 SABCS, emphasizing its critical role in monitoring molecular residual disease in early breast cancer, which could advance precision medicine.
  • Clinical Trial Progress: The SURVIVE HERoes Phase III trial will explore the application of RaDaR testing in molecular relapse monitoring, and positive results could provide new strategies for personalized treatment, enhancing patient survival rates.
  • Long-term Tracking Study: Five-year follow-up data from the CLEVER trial show that RaDaR-detected ctDNA is often present months before clinical recurrence, highlighting its potential in monitoring long-term risks and possibly changing standards for post-treatment care in breast cancer.
  • Industry Impact: CEO Tony Zook stated that these studies provide crucial evidence for integrating MRD insights into routine oncology care, potentially enhancing the treatment capabilities of community oncologists.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Neogenomics Inc (NEO) stock price today?

The current price of NEO is 11.85 USD — it has increased 0.68 % in the last trading day.

arrow icon

What is Neogenomics Inc (NEO)'s business?

NeoGenomics, Inc. is a cancer diagnostics company specializing in cancer genetics testing and information services. The Company offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing; interpretation and consultative services; molecular and NGS testing; comprehensive technical and professional services offering; clinical trials and research; validation laboratory services, and oncology data solutions. It operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics (karyotype analysis), Fluorescence In-Situ Hybridization (FISH), Flow cytometry, and others.

arrow icon

What is the price predicton of NEO Stock?

Wall Street analysts forecast NEO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NEO is 13.67 USD with a low forecast of 11.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Neogenomics Inc (NEO)'s revenue for the last quarter?

Neogenomics Inc revenue for the last quarter amounts to 187.80M USD, increased 11.90 % YoY.

arrow icon

What is Neogenomics Inc (NEO)'s earnings per share (EPS) for the last quarter?

Neogenomics Inc. EPS for the last quarter amounts to -0.21 USD, increased 50.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Neogenomics Inc (NEO)'s fundamentals?

The market is revising Upward the revenue expectations for NeoGenomics, Inc. (NEO) for FY2025, with the revenue forecasts being adjusted by 0.43% over the past three months. During the same period, the stock price has changed by 48.87%.
arrow icon

How many employees does Neogenomics Inc (NEO). have?

Neogenomics Inc (NEO) has 2200 emplpoyees as of December 13 2025.

arrow icon

What is Neogenomics Inc (NEO) market cap?

Today NEO has the market capitalization of 1.53B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free